FDA Logo--links to FDA home page
U.S. Food and Drug Administration
 HHS Log--links to Department of Health and Human Services website

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | FDA Centennial


horizontal rule

Nanoparticle albumin bound (nab) Technology

Neil Desai

 

Index of Slides : Graphic Version 800x600

  1. Nanoparticle albumin bound (nab) technology : A nanotechnology platform for biologically interactive drug delivery and targeting
  2. Nanoparticle Albumin-bound (nab) platform technology
  3. Abraxane (nab-paclitaxel) is a solvent-free ‘nano’ version of Taxol (cremophor-based paclitaxel)
  4. Abraxane approved by FDA with about twice the response rate of Taxol in metastatic breast cancer
  5. A key aspect of nanoparticle stability of nab-paclitaxel is size and zeta potential
  6. Nanoparticle Release of nab-paclitaxel in simulated plasma measured by Laser Light Scattering
  7. Nab-platform utilizes endogenous albumin pathways of endothelial transcytosis (gp60) and intratumoral binding of SPARC
  8. Rapid Tumor Accumulation of nab-paclitaxel in tumor
  9. Comparing ‘nano’ paclitaxel vs standard paclitaxel
  10. Definitions of Nanotechnology adopted by FDA
  11. Nanotechnology / drug-delivery literature review: Is the 100 nm cutoff appropriate? Search: Pubmed/Internet [keywords: nanoparticle AND size AND drug AND delivery]
  12. Meeting current definitions of Nanotechnology : Other nab products in development
  13. Recommendations for revising current definitions of size range/function for nanotechnology drug products

Return to Format List

horizontal rule

Public Meeting on Nanotechnology Materials

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility

FDA Website Management Staff